The global chronic refractory cough treatment market is forecast to experience significant growth. A recent report published by Future Market Insights expects the market to grow at a CAGR of 6.39% from 2023 to 2033, expected to close at a valuation of US$ 17.1 billion. Many patients with chronic cough require multiple clinical encounters to obtain a diagnosis, with over half remaining undiagnosed. However, the last decade witnessed significant scientific achievement in understanding the mechanisms of chronic cough, which has led to multiple clinical drug development programs exploring potential novel agents. Also, a rise in healthcare spending & R&D and better awareness around the condition are anticipated to drive market growth.
A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16436
Another significant factor influencing the growth of chronic refractory cough treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, several government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Healthcare industries are investing in opiates and GABA (gamma-aminobutyric acid)-related substances to help people with cough hypersensitivity. To treat chronic intractable cough, opiates are excellent cough suppressants and have antitussive actions. Similarly, corporations are expanding their tramadol production capabilities, an opioid prescription with a chemical makeup comparable to codeine medicines which augments market expansion.
Also, surging geriatric population and sedentary lifestyle of people such as high addiction of smoking will result in the market expansion of chronic refractory cough treatment. Along with this, favorable reimbursement policies and increasing number of government initiatives to spread awareness will enhance growth of the market. Over the forecast period, the market of chronic refractory cough treatment is anticipated to develop owing to increase in the number of clinical trials. This is expected to boost new market opportunities. The recent success of a P2X3 receptor antagonist in randomized clinical trials is the first major advancement in cough treatments in 30 years; it finally gives a method for treating persistent cough as well as a useful tool for unravelling the mechanism underlying cough hypersensitivity.
The market’s growth is also fuelled by growth in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the chronic refractory cough treatment market growth. On the other hand, high cost associated with the treatment will restrict the growth rate of market. The dearth of healthcare infrastructure in developing economies and lack of skilled professionals will hamper the market of chronic refractory cough. Additionally, lack of awareness among people and inefficiency of drugs along with its adverse effects will act as barriers and further impede the growth rate of market during the forecast period.
Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16436
Key Takeaways from the Market Study
- North America is expected to dominate the market of Chronic refractory cough treatment with 40% market share by end of the forecast period.
- The market in South Asia is projected to reflect fastest CAGR of 6.2%
- By distribution channel, retail pharmacies are expected to dominate the market with 55% market share.
- Online Pharmacies segment is estimated to grow with fastest CAGR of 8% during the forecast period.
- By drug class, antibiotics are expected to lead the segment with 45.7% market share by end of 2033.
“Growth in the number of research and development activities and rising healthcare expenditure will drive market growth”- says an FMI Analyst
Competitive Landscape
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost market growth. The major players in the market are: Bayer AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Mylan N.V., GlaxoSmithKline, Hikma Pharmaceuticals Plc, AstraZeneca, Bausch Health, Novartis AG, Cipla Inc, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd, Alitair Pharmaceuticals, NeRRe Therapeutics, Amneal Pharmaceuticals, Inc
Some recent developments in this industry are:
- On September 6, 2021, Bayer announced the results from PAGANINI, the Phase IIb dose-finding study evaluating the efficacy and safety of its investigational orally administered, potent and selective P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough (RCC). The primary efficacy outcome was met showing a statistically significant reduction in the 24-hour cough count (average hourly cough frequency based on 24-hour sound recordings) of up to 27% for eliapixant 75 mg twice daily over placebo after 12 weeks of treatment.
Key Segments Profiled in the Chronic Refractory Cough Treatment Industry Survey
By Drug Class:
- Antibiotics
- Decongestants
- Corticosteroids
- Antihistamines
- Acid Blockers
- Others
By Route of administration:
- Oral
- Nasal
- Parenteral
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Visit For Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16436
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global chronic refractory cough treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the chronic refractory cough treatment market, the market is segmented on the basis of drug class (Antibiotics, Decongestants, Corticosteroids, Antihistamines, Acid Blockers, Others) By Route of administration (Oral, Nasal, Parenteral, others) By Distribution channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) By region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs